Auxilium gains rights to Vivus ED drug for USA and Canada

11 October 2013

Auxilium Pharmaceuticals (Nasdaq: AUXL) has signed an agreement with fellow USA-based Vivus (Nasdaq: VVUS) providing Auxilium with the exclusive right to market Vivus’ erectile dysfunction (ED) product Stendra (avanafil) in the USA and Canada.

The parties also simultaneously signed a commercial supply agreement pursuant to which Vivus will be initially responsible for the manufacture and supply of Stendra, which is already approved by the Food and Drug Administration.

Under the license, Auxilium will pay Vivus a one-time license fee of $30 million. Auxilium may make a $15 million regulatory milestone payment to VIVUS if the FDA approves the Stendra label to reflect a 15 minute or less onset of action efficacy claim and up to $255 million in potential milestone payments based on the achievement of certain sales targets. Vivus will also receive royalties on product sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical